Compare AU

Compare XASG vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

Alphinity Global Sustainable Equity Fund - Active ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are XASG and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

XASG

DRUG

Popularity

N/A

Low

Pearlers invested

0

63

Median incremental investment

$0

$967.00

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,875.72

Average age group

N/A

26 - 35


Key Summary

XASG

DRUG

Strategy

XASG.AX was created on 2021-06-02 by Alphinity. The fund's investment portfolio concentrates primarily on total market equity. The Fund primarily invests in a diversified portfolio of leading global sustainable companies, which are aligned with one or more of the United Nations Sustainable Development Goals (SDGs), with strong ESG characteristics.

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

Alphinity Global Sustainable Equity Fund - Active ETF (100 %)

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Top 3 industries

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.75 %

0.57 %


Key Summary

XASG

DRUG

Issuer

Alphinity

BetaShares

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.75 %

0.57 %

Price

$7.46

$8.12

Size

N/A

$182.401 million

10Y return

N/A

N/A

Annual dividend/ distribution yield (5Y)

0.46 %

1.90 %

Market

ASX

ASX

First listed date

16/01/2023

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

XASG

DRUG

Popularity

N/A

Low

Pearlers invested

0

63

Median incremental investment

$0

$967.00

Median investment frequency

N/A

Monthly

Median total investment

$0

$1,875.72

Average age group

N/A

26 - 35


Pros and Cons

XASG

DRUG

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

XASG

DRUG

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home